.jpg "Pluristem (NASDAQ: PSTI)")
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Pluristem (NASDAQ: PSTI) today and set a price target of $3.50. The company’s shares closed yesterday at $1.31.
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 7.9% and a 42.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Leap Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Pluristem with a $3.67 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.12 and a one-year low of $1.14. Currently, Pluristem has an average volume of 205.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pluristem Therapeutics, Inc. is a biotechnology company, which engages in the provision of cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions.
